Optimization of Golimumab Treatment in Ulcerative Colitis

NCT03669029 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg
DRUG: Golimumab treatment optimization.

Sponsor

Hospital de Manises

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]